Anavex reports blarcamesine yields near-normal aging cognition in Alzheimer’s trial

Anavex Life Sciences has announced findings from its Phase IIb/III Alzheimer’s trial in which 30 mg daily oral blarcamesine led to cognitive outcomes in a “Precision Medicine” population (called ABCLEAR3) that the company says approximate normal aging rather than typical Alzheimer’s decline. The results cover 48 weeks in early Alzheimer’s disease patients with progressed pathology. […] The post Anavex reports blarcamesine yields near-normal aging cognition in Alzheimer’s trial appeared first on Longevity.Technology.